

Bosch, Randox invest €150 million in Vivalytic platform

April 10, 2024—[Bosch](#) and [Randox Laboratories](#) have entered into a strategic partnership in which the two companies will invest around €150 million in joint research, development, and distribution for new tests for Bosch's Vivalytic platform. One goal of the partnership is to develop an in vitro diagnostic, multiplex sepsis test for the Vivalytic analyzer. It will be the first test to feature Bosch's novel BioMEMS technology.

"Current methods of sepsis diagnosis are insufficient and time-consuming. With over 10 years of experience in the field of infectious diseases diagnostics, we aim to develop a state-of-the-art sepsis test using the highly multiplexing BioMEMS technology," said Dr. Peter FitzGerald, managing director of Randox. "Such a test could revolutionize sepsis diagnosis, ultimately leading to improved treatment outcomes and lower mortality rates from this life-threatening condition."

The companies said they aim to achieve sales in the nine-figure range by 2030.